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A B S T R A C T
Purpose
Although advances in Hodgkin lymphoma (HL) treatment have led to improved disease-free survival,
this has been accompanied by an increased risk of second cancers. We sought to quantify the
second cancer risks and to investigate the impact of family history.
Patients and Methods
Using the Swedish Family-Cancer Project Database, we identiﬁed 9,522 individuals with primary HL
diagnosed between 1965 and 2012. We calculated standardized incidence ratios and cumulative
incidence of second cancer in HL survivors and compared the standardized incidence ratios of lung,
breast, colorectal, and all second cancers in HL survivors with and without a site-speciﬁc family
history of cancer. Interactions between family history of cancer and HL treatment were evaluated
under additive and multiplicative models.
Results
Overall, the risk of a second cancer in HL survivors was increased 2.39-fold (95% CI, 2.29 to 2.53).
The 30-year cumulative incidence of breast cancer in women diagnosed with HL at younger than 35
years of age was 13.8%. We observed no signiﬁcant difference in cancer risk over successive time
periods. The risk of all second cancerswas 1.3-fold higher for HL survivorswith a ﬁrst-degree relative
with cancer (P, .001), with 3.3-fold, 2.1-fold, and 1.8-fold differences shown for lung, colorectal, and
breast cancers, respectively. Moreover, a greater than additive interaction between family history of
lung cancer and HL treatment was shown (P = .03).
Conclusion
HL survivorship is associated with a substantive risk of a second cancer. Notably, the risk is higher in
individuals with a family history of cancer. This information should be used to inform risk-adapted
therapy and to assist in screening to reduce long-term morbidity and mortality in patients with HL.
J Clin Oncol 35:1584-1590. © 2017 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Advances in the management of Hodgkin
lymphoma (HL) over the past 40 years have led
to improved disease-free survival in patients.1
However, this comes at the cost of an increased
risk of second cancers, cardiovascular disease,
and other treatment-related complications.2-13
The risk of second cancers in HL survivors,
which persists for many decades after treatment,
has been reported to be inﬂuenced by various
factors, including age at treatment,3 site and
dose of radiotherapy,14 chemotherapy,5 and
smoking.15 The use of treatment regimens based
on a reduction in the ﬁeld and dose of radio-
therapy and alkylating chemotherapy has been
introduced to reduce rates of long-term com-
plications while maintaining a high cure rate.1
Despite such modiﬁcations, a recent study from
the Netherlands showed that this has not af-
fected the risk of second cancers in patients with
HL12.
A family history of breast cancer was ﬁrst
suggested to be a risk factor for second cancer in
HL nearly 20 years ago,16 and it has long been
postulated that a subset of patients with cancer
display a high sensitivity to mutational agents
because of a genetic predisposition.17 Evidence for
such an assertion in the context of HL is provided
by an analysis of a Swedish cohort of patients with
HL, but the power of the study did not allow the
impact of family history to be studied in detail.18
Moreover, the analysis included HL survivors
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with a prior history of cancer other than HL, which potentially
biased the conclusions.
To gain insight into the risk of second cancer after a diagnosis
of HL and its relationship to temporal changes in treatment
regimens, we analyzed data on a cohort of 9,522 Swedish patients.
In addition, through the use of the Swedish Family-Cancer Project
Database, we performed an updated analysis of the inﬂuence of
family history, as a surrogate for genetic susceptibility, on the risk
of second cancer in patients with HL.
PATIENTS AND METHODS
Patients
The Swedish Family-Cancer Project Database was created by linking
information from the multigeneration register, national censuses, the
Swedish Cancer Registry, and death notiﬁcations.19 The Swedish Cancer
Registry, established in 1958, is based on the compulsory reporting of all
diagnosed patients, thereby providing near-complete coverage of all cancer
registrations in Sweden.20 There is an under-representation of individuals
in the ﬁrst generation in some families; however, this has not been shown
to adversely bias estimates of familial risk.21,22 In this study, we analyzed all
incident cases of HL between 1965 and 2012. Individuals with a diagnosis
of malignancy before HL were excluded. Individuals with HL were ob-
served until December 31, 2012, time of migration from Sweden, or death.
Data regarding HL histologic subtype were available for all individuals
diagnosed since 1993. The database includes the date and site of occurrence
of up to four subsequent new malignancies after diagnosis of HL and dates
and causes of death. Cancers in the ﬁrst year after HL diagnosis were
omitted from our analysis because of the likelihood of excess cases as
a result of increased surveillance.23 First-degree relatives (FDRs) of in-
dividuals with HL, as well as the dates and sites of cancer diagnoses in the
FDRs, were identiﬁed. The study was undertaken with approval from the
ethics committee at Lund University, Sweden, and was conducted in ac-
cordance with the tenets of the Declaration of Helsinki.
Statistical Analysis
Expected numbers of cancers were computed using 5-year age, sex,
and calendar period incidence rates for Sweden. Observed numbers were
compared with expected numbers by means of the standardized incidence
ratio (SIR) assuming a Poisson distribution. The risk of a second ma-
lignancy was estimated for different time intervals after treatment of HL.
The absolute excess risk (AER) was calculated as the observed number of
second cancers in our cohort minus that expected, divided by the number
of person-years at risk, multiplied by 10,000. SIRs were calculated in the
HL cohort and were stratiﬁed by patient characteristics. Tests for trend in
SIRs were performed by evaluating the likelihood function in collapsed
person-time additive Poisson regression models with and without the
inclusion of the variable. Patients in whom multiple second cancers were
diagnosed were counted only once in the analysis of all second cancers; in
this analysis, the time at risk ended on the date on which a second cancer
was diagnosed. For the site-speciﬁc cancer analyses, the time at risk ended
on the date on which the site-speciﬁc cancer was diagnosed, regardless of
whether this was preceded by another cancer. The cumulative incidence of
second cancer was estimated with death treated as a competing risk.24
Interaction contrast ratios (ICRs) and multiplicative interaction indexes
(MIIs) were used to investigate the possible interaction between HL
treatment and family history of cancer:25 ICR = SIRcancerxfh 2 SIRcancer 2
SIRfh + 1 and MII = SIRcancerxfh/(SIRcancer 3 SIRfh), where SIRcancer is the
relative risk (RR) of cancer in HL survivors, SIRfh is the RR associated with
having an affected FDR, and SIRcancerxfh is the RR of cancer in HL survivors
having an affected FDR. MII . 1 signiﬁes greater than multiplicative
interaction, and ICR . 0 signiﬁes a positive interaction or more than
additivity. The relative survival rate was calculated as the ratio of the
observed survival rate to the expected survival rate in Sweden, matched by
age, sex, and calendar year.26,27 Statistical analyses were performed using
Stata version 14 (STATA, College State, TX) and R version 3.3.1 software.28
A P value # .05 (two-sided) was considered statistically signiﬁcant, al-
though we acknowledge we have presented the results of many statistical
tests, and therefore caution against the overinterpretation of our ﬁndings,
especially when they are based on P values . .001.
RESULTS
Patients and Record Linkage
From the Swedish Family-Cancer Project Database, data on
9,522 patients with a primary diagnosis of HL between 1965 and
2013 were analyzed. Of the 9,522 patients 5,488 were male and
4,034 were female, with a mean age at diagnosis of 49 years
(Table 1). Five thousand seven hundred twenty-one were deceased
and 129 had emigrated before the end of the study period. The
median follow-up was 12.6 years, with the longest being 48 years.
Of patients with HL in whom tumor with histology had been
recorded, 1,839 (54%) were nodular sclerosis HL (NSHL) and 539
(16%) were of mixed cellularity HL. Among the 3,917 individuals
who died. 1 year after the diagnosis of HL, 842 (9%) died with the
occurrence of a subsequent cancer during the follow-up.
Risk of Second Cancer in Patients With HL
A total of 1,215 second cancers were observed in 1,121 patients
(12% of patients with HL). The risk of all second cancers was
elevated signiﬁcantly after HL diagnosis, with a SIR of 2.39 (95%
CI, 2.25 to 2.53), translating to an AER of 71.2 cases per 10,000
person-years (Table 2). In the nonstratiﬁed analysis, non-Hodgkin
lymphoma (NHL) contributed the most to the AER (16.2% of the
excess cancer risk), followed by lung cancer (14.5% of the excess
cancer risk), breast cancer (12.9% of the excess cancer risk),
Table 1. Clinicopathologic Characteristics of Patients With Hodgkin
Lymphoma Diagnosed Between 1965 and 2013 in Sweden
Characteristic
No. patients 9,522
Male 5,488
Female 4,034
Diagnosis year, range 1965-2012
Mean age at diagnosis, years (range) 49 (3-100)
Histology (No.)
Nodular sclerosis 1,839
Mixed cellularity 529
Modular lymphocyte predominant 270
Lymphocyte depleted 53
Other 3
Unspeciﬁed 695
No. deceased 5,721
Mean age at death, years (range) 65 (6-105)
No. patients with follow-up . 1 year 7,691
Mean follow-up, years* 12.6 (1-48)
No. ﬁrst-degree relatives 28,277†
Parents 8,806
Siblings 6,782
Offspring 12,751
*Calculated for patients with a follow-up of $ 1 year.
†Unique individuals.
jco.org © 2017 by American Society of Clinical Oncology 1585
Family History and Second Cancer Risk in Hodgkin Lymphoma
Downloaded from ascopubs.org by INSTITUTE CANCER RESEARCH on September 21, 2017 from 193.062.218.079
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Ta
bl
e
2.
R
is
k
of
S
ec
on
d
C
an
ce
r
at
1
to
9,
10
to
19
,
20
to
30
,
an
d
.
30
Y
ea
rs
A
ft
er
D
ia
gn
os
is
of
H
od
gk
in
Ly
m
ph
om
a
C
an
ce
r
S
ite
Y
ea
rs
A
ft
er
Tr
ea
tm
en
t
1-
9
10
-1
9
20
-3
0
.
30
.
1
A
E
R
N
o.
S
IR
(9
5%
C
I)
N
o.
S
IR
(9
5%
C
I)
N
o.
S
IR
(9
5%
C
I)
N
o.
S
IR
(9
5%
C
I)
N
o.
S
IR
(9
5%
C
I)
C
an
ce
r
ov
er
al
l
58
0
2.
12
(1
.9
6
to
2.
30
)*
31
3
2.
92
(2
.6
1
to
3.
26
)*
16
5
2.
55
(2
.1
9
to
2.
98
)*
63
2.
65
(2
.0
7
to
3.
39
)*
11
21
2.
39
(2
.2
5
to
2.
53
)*
71
.2
P
ha
ry
nx
7
4.
25
(2
.0
3
to
8.
92
)*
3
3.
79
(1
.2
2
to
11
.7
4)
†
1
2.
01
(0
.2
8
to
14
.2
3)
11
3.
52
(1
.9
5
to
6.
35
)*
0.
8
E
so
ph
ag
us
2
0.
72
(0
.1
8
to
2.
90
)
5
4.
33
(1
.8
0
to
10
.4
1)
*
2
2.
71
(0
.6
8
to
10
.8
3)
4
12
.8
4
(4
.8
2
to
34
.2
)*
13
2.
62
(1
.5
2
to
4.
51
)*
0.
8
S
to
m
ac
h
18
1.
58
(0
.9
9
to
2.
50
)
9
2.
53
(1
.3
1
to
4.
85
)‡
2
1.
11
(0
.2
8
to
4.
42
)
2
3.
06
(0
.7
7
to
12
.2
4)
31
1.
78
(1
.2
5
to
2.
52
)‡
1.
4
C
ol
on
43
2.
00
(1
.4
9
to
2.
70
)*
24
2.
80
(1
.8
7
to
4.
17
)*
12
2.
26
(1
.2
8
to
3.
98
)‡
4
1.
82
(0
.6
8
to
4.
86
)
83
2.
21
(1
.7
8
to
2.
74
)*
4.
7
R
ec
tu
m
19
1.
47
(0
.9
4
to
2.
30
)
7
1.
29
(0
.6
1
to
2.
70
)
4
1.
17
(0
.4
4
to
3.
12
)
2
1.
41
(0
.3
5
to
5.
64
)
32
1.
38
(0
.9
7
to
1.
95
)
0.
9
C
ol
or
ec
tu
m
60
1.
75
(1
.3
6
to
2.
25
)*
30
2.
16
(1
.5
1
to
3.
09
)*
16
1.
85
(1
.1
3
to
3.
02
)†
6
1.
68
(0
.7
6
to
3.
75
)
11
2
1.
85
(1
.5
4
to
2.
23
)*
5.
4
H
ep
at
ob
ili
ar
y
11
1.
48
(0
.8
2
to
2.
68
)
3
1.
09
(0
.3
5
to
3.
37
)
3
2.
00
(0
.6
5
to
6.
20
)
1
1.
80
(0
.2
5
to
12
.7
7)
18
1.
47
(0
.9
3
to
2.
34
)
0.
6
P
an
cr
ea
s
11
1.
37
(0
.7
6
to
2.
47
)
11
3.
68
(2
.0
4
to
6.
64
)*
5
2.
96
(1
.2
3
to
7.
12
)†
1
1.
51
(0
.2
1
to
10
.6
9)
28
2.
09
(1
.4
4
to
3.
03
)*
1.
5
Lu
ng
56
2.
65
(2
.0
4
to
3.
44
)*
40
4.
48
(3
.2
8
to
6.
10
)*
31
5.
41
(3
.8
0
to
7.
69
)*
11
4.
52
(2
.5
0
to
8.
16
)*
13
8
3.
61
(3
.0
5
to
4.
36
)*
10
.3
B
re
as
t
39
1.
27
(0
.9
3
to
1.
74
)
64
4.
16
(3
.2
5
to
5.
31
)*
34
3.
92
(2
.8
0
to
5.
48
)*
9
3.
01
(1
.5
7
to
5.
78
)*
14
6
2.
52
(2
.1
5
to
2.
97
)*
9.
2
U
te
rin
e
9
1.
48
(0
.7
7
to
2.
84
)
3
2.
74
(0
.3
5
to
3.
40
)
1
0.
55
(0
.0
8
to
3.
90
)
1
1.
27
(0
.1
8
to
9.
00
)
14
1.
22
(0
.7
3
to
2.
07
)
0.
3
P
ro
st
at
e
59
1.
20
(0
.9
3
to
1.
55
)
28
1.
32
(0
.9
1
to
1.
91
)
15
0.
95
(0
.5
7
to
1.
57
)
11
1.
51
(0
.8
4
to
2.
73
)
11
3
1.
21
(1
.0
1
to
1.
46
)†
2.
1
K
id
ne
y
10
1.
09
(0
.5
8
to
2.
02
)
8
2.
24
(1
.1
3
to
4.
50
)†
3
1.
48
(0
.4
8
to
4.
60
)
2
2.
61
(0
.6
5
to
10
.4
3)
23
1.
48
(0
.9
8
to
2.
22
)
0.
8
B
la
dd
er
21
1.
54
(1
.0
0
to
2.
26
)
8
1.
36
(0
.6
8
to
2.
72
)
9
2.
44
(1
.2
6
to
4.
68
)†
1
0.
65
(0
.0
9
to
4.
61
)
39
1.
57
(1
.1
5
to
2.
15
)‡
1.
5
M
el
an
om
a
25
2.
34
(1
.5
8
to
3.
46
)*
9
1.
69
(0
.8
8
to
3.
25
)
6
2.
00
(0
.9
0
to
4.
44
)
2
1.
78
(0
.4
4
to
7.
10
)
42
2.
08
(1
.5
4
to
2.
82
)*
2.
3
S
C
C
(s
ki
n)
59
4.
91
(3
.8
0
to
6.
35
)*
25
4.
66
(3
.1
5
to
6.
89
)*
11
3.
52
(1
.7
3
to
5.
64
)*
5
3.
13
(1
.3
0
to
7.
52
)‡
10
0
4.
44
(3
.6
5
to
5.
41
)*
8.
1
B
ra
in
15
2.
06
(1
.2
4
to
3.
42
)‡
9
3.
06
(1
.5
9
to
5.
89
)*
5
3.
29
(1
.3
7
to
7.
91
)‡
3
4.
60
(1
.4
8
to
14
.2
7)
†
32
2.
58
(1
.8
3
to
3.
65
)*
2.
1
Th
yr
oi
d
10
4.
18
(2
.2
5
to
7.
76
)*
8
8.
38
(4
.2
0
to
16
.7
7)
*
2
4.
71
(1
.1
7–
18
.8
3)
†
20
5.
13
(3
.3
1
to
7.
94
)*
1.
8
C
on
ne
ct
iv
e
tis
su
e
7
3.
50
(1
.6
7
to
7.
35
)*
7
8.
20
(3
.9
1
to
17
.2
1)
*
4
8.
67
(3
.2
5
to
23
.0
6)
*
2
11
.4
3
(2
.8
6
to
45
.7
2)
*
20
5.
73
(3
.7
0
to
8.
89
)*
1.
7
N
H
L
68
8.
03
(6
.3
3
to
10
.1
8)
*
33
8.
32
(5
.8
8
to
11
.7
9)
*
21
9.
08
(5
.9
2
to
13
.9
2)
*
3
3.
38
(1
.0
9
to
10
.4
6)
†
12
5
7.
99
(6
.7
0
to
9.
53
)*
11
.5
Le
uk
em
ia
60
8.
54
(6
.6
3
to
11
.0
0)
*
10
3.
51
(1
.8
9
to
6.
52
)*
8
4.
77
(2
.3
9
to
9.
54
)*
1
1.
51
(0
.2
1
to
10
.6
8)
79
6.
46
(5
.1
9
to
8.
06
)*
6.
9
A
bb
re
vi
at
io
ns
:
A
E
R
,
ab
so
lu
te
ex
ce
ss
ris
k
(N
o.
/1
0,
00
0
pe
rs
on
-y
ea
rs
);
N
H
L,
no
n-
H
od
gk
in
ly
m
ph
om
a;
S
C
C
,
sq
ua
m
ou
s
ce
ll
ca
rc
in
om
a;
S
IR
,
st
an
da
rd
iz
ed
in
ci
de
nc
e
ra
tio
.
*P
,
.0
01
.
†
P
,
.0
5.
‡
P
,
.0
1.
1586 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Sud et al
Downloaded from ascopubs.org by INSTITUTE CANCER RESEARCH on September 21, 2017 from 193.062.218.079
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
nonmelanoma skin cancers (11.4% of the excess cancer risk),
leukemia (9.7% of the excess cancer risk), and colorectal cancer
(7.6% of the excess cancer risk). The SIR for all second cancers
remained high . 30 years after treatment of HL, although the
patterns of excess risk observed at the different intervals differed
depending on the cancer site (Table 2).
Influence of Sex, Age, and Tumor Subtype on Second
Cancer Risk
For men diagnosed with HL before the age of 35 years, the
SIRs for all second cancers, colorectal cancer, lung cancer, NHL,
and leukemia were higher when compared with those diagnosed
with HL after the age of 35 years. Similarly, for women diagnosed
with HL before the age of 35 years, the SIRs for all second cancers,
breast cancer, lung cancer, and NHL were higher when compared
with women diagnosed with HL after the age of 35 years (Table 3).
In women diagnosed with HL at younger than 35 years of age, the
30-year cumulative risk of breast cancer was 13.8% (95% CI, 11.1
to 16.9), which accounted for. 50% of the AER in this age group
of women. This contrasted with women diagnosed with HL at
older than 35 years of age for whom the 30-year cumulative
incidence of breast cancer was only 3.3% (95% CI, 2.2 to 3.9), and
accounted for , 3% of the AER (Fig 1 and Data Supplement).
Given the difference in cause and tumor biology of HL histologic
subtypes, we investigated whether second cancer risk might also
differ. We observed similar SIRs for cancer overall and the
common site-speciﬁc cancers for the most common subtype,
NSHL (Data Supplement). We do acknowledge, however, that
this observation should be interpreted with caution because
numbers are small and the unclassiﬁed HL cases include a pro-
portion of NSHL.
Temporal Effects on Risk of Second Cancer
Although details of individual patient therapy are not
registered by the Swedish Cancer Registry, the treatment prin-
ciples for HL in Sweden are broadly similar to those of other
Western countries.29 Brieﬂy, extended ﬁeld irradiation, mainly
mantle ﬁeld, was the standard treatment of patients with HL
during the early phase of our analysis. Patients received ra-
diotherapy, chemotherapy, or a combined modality treatment.
For those patients treated after 1990, less toxic regimens were
being introduced.29,30 Partitioning data, we analyzed the second
cancer risk for patients diagnosed with HL in the time periods of
1965 to 1977, 1978 to 1988, and 1989 to 2000. We found little
evidence of a change in SIRs for overall cancer and for the most
common sites of cancer, including hematopoietic malignancy
(Data Supplement).
Impact of Family History on Risk of Second Cancer and
Survival
From theMultigenerational Register, a total of 28,277 FDRs of
the 9,522 patients with HL were identiﬁed. The SIR for cancer risk
in FDRs was 1.02 (95%CI, 0.99 to 1.06). In the HL survivors, 2,785
individuals (29%) had one or more FDRs with a family history of
cancer (Data Supplement). We found an increase in second cancer
risk in HL survivors who had an FDR with cancer, when compared
with HL survivors with no FDRwith cancer (P, .001) with SIRs of
2.83 (95% CI, 2.58 to 3.10) and 2.16 (95% CI, 2.00 to 2.33),
respectively. Moreover, the increased risk of second cancer was
correlated with the number of FDRs affected with cancer, re-
spective SIRs being 2.67 (95% CI, 2.40 to 2.97) and 3.40 (95% CI,
2.85 to 4.09) for patients with one and two or more affected FDRs
(P , .001; Data Supplement).
Table 3. Risk of Second Cancer After Diagnosis of Hodgkin Lymphoma by Sex and Age at HL Diagnosis
Cancer Site
, 35 Years Old $ 35 Years Old
P*No. SIR (95% CI) AER
30-Year Cumulative
Incidence (95% CI) No. SIR (95% CI) AER
30-Year Cumulative
Incidence (95% CI)
Male
Cancer overall 183 4.26 (3.68 to 4.92)† 47 13.9 (11.6 to 16.4) 491 2.08 (1.91 to 2.28)† 111 20.4 (18.8 to 22.0) , .001
Colorectum 18 4.07 (2.57 to 6.46)† 4 1.4 (0.7 to 2.3) 55 1.73 (1.33 to 2.26)† 10 2.2 (1.6 to 2.8) , .001
Lung 19 6.16 (3.93 to 9.66)† 5 2.0 (1.1 to 3.3) 76 3.20 (2.56 to 4.00)† 21 3.0 (2.3 to 3.8) .02
Breast 1 12.60 (1.78 to 89.43)‡ 0.3 0.1 (0 to 0.6) 2 4.58 (1.14 to 18.29)§ 0.6 0.1 (0 to 0.3) .44
SCC (skin) 8 5.89 (2.94 to 11.77)† 2 0.5 (0.2 to 1.1) 54 3.96 (3.03 to 5.18)† 17 2.0 (1.5 to 2.7) .32
Non-Hodgkin
lymphoma
33 15.9 (11.28 to 22.32)† 10 2.9 (1.9 to 4.2) 55 6.93 (5.32 to 9.02)† 19 2.4(1.8 to 3.1) , .001
Leukemia 19 12.15 (7.75 to 19.05)† 5 1.5 (0.8 to 2.3) 36 5.57 (4.02 to 7.72)† 12 1.3 (0.9 to 1.8) .01
Female
Cancer overall 188 4.61 (3.99 to 5.32)† 64 24.5 (21.0 to 28.2) 259 1.73 (1.53 to 1.96)† 67 14.9 (13.3 to 16.6) , .001
Colorectum 4 1.31 (0.49 to 3.48) 0.4 0.6 (0.2 to 1.7) 35 1.65 (1.19 to 2.30)‡ 8 2.1 (1.5 to 2.9) .65
Lung 20 8.84 (5.70 to 13.70)† 7 2.6 (1.40 to 4.40) 23 2.50 (1.67 to 3.77)† 8 1.4 (0.9 to 2.2) , .001
Breast 96 6.00 (4.91 to 7.33)† 34 13.8 (11.1 to 16.9) 47 1.14 (0.85 to 1.51) 3 3.3 (2.2 to 3.9) , .001
SCC (skin) 5 6.37 (2.65 to 15.31)† 2 0.1 (0.0 to 1.6) 33 4.87 (3.46 to 6.85)† 15 1.9 (1.3 to 2.7) .29
Non-Hodgkin
lymphoma
7 6.23 (2.96 to 13.04)† 3 0.8 (0.3 to 1.9) 30 6.55 (4.58 to 9.37)† 15 1.6 (1.1 to 2.4) .90
Leukemia 9 10.36 (5.39 to 19.92)† 3 0.6 (0.2 to 1.2) 15 4.51 (2.72 to 7.48)† 7 0.9 (0.5 to 1.4) .05
Abbreviations: AER, absolute excess risk (No./10,000 person-years); HL, Hodgkin lymphoma; SCC, squamous cell carcinoma; SIR, standardized incidence ratio.
*Test of difference between SIRs.
†P , .001.
‡P , .01.
§P , .05.
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In an analysis of colorectal, breast, and lung cancer, we ob-
served elevated risks of second cancers in HL survivors with an
FDR with the corresponding site-speciﬁc cancer. For lung cancer,
SIRs were 11.24 (FDR with lung cancer; 95%CI, 6.38 to 19.79) and
3.39 (no FDR with lung cancer; 95% CI, 2.85 to 4.03; P , .001).
For colorectal cancer, SIRs were 3.71 (FDR with colorectal cancer;
95% CI, 2.05 to 6.70) and 1.76 (no FDR with colorectal cancer;
95% CI, 1.45 to 2.14; P = .03). Finally, for breast cancer, SIRs were
4.36 (FDR with breast cancer; 95% CI, 2.60 to 6.55) and 2.36 (no
FDR with breast cancer; 95% CI, 1.98 to 2.81; P = .04; Table 4).
Moreover, for lung cancer, a more than additive interaction be-
tween family history and HL treatment was shown (P = .03;
Table 5). Overall, having a family history of cancer was shown not
to inﬂuence survival from a second cancer in patients with HL
(Data Supplement).
DISCUSSION
This analysis provides further evidence that survivorship from HL
is associated with a signiﬁcant risk of a second cancer. Further-
more, we conﬁrm the previous ﬁndings of a relationship between
age at diagnosis and sex, and the risk of second cancers. Our
analysis also shows that differences in patient management over
successive decades have not led to a lessening of risk of second
cancers in HL survivors, an observation consistent with recent data
from the Netherlands.12 Possible reasons for this observation
include the impact of screening or that the risk is maintained
because of an interaction between less toxic chemotherapy and
second cancer risk. For example, higher doses of alkylating agents,
which are more likely to cause premature menopause, have been
reported to reduce radiation-induced breast cancer risk.31 In
addition, although patients diagnosed with HL are likely to have
received lower doses of alkylating agents in recent years, the
omission of radiotherapy from such treatment regimens is likely to
have led to an increased proportion of all patients receiving
alkylating agents.12 Finally, we cannot exclude entirely the possi-
bility that the study periods we analyzed were too short or early to
be able to demonstrate a difference.
In this study, HL survivors with a family history of colorectal,
lung, or breast cancer showed an increased risk of concordant
second cancers when compared with HL survivors without a family
history. To our knowledge, this is the ﬁrst population study to
demonstrate site-speciﬁc second cancer risk after HL being
inﬂuenced by family history. Our ﬁndings support the notion of
familial determinants of second cancer risk being consistent with
inherited genetic predisposition. Direct evidence for such a model
is provided by the example of retinoblastoma, in which individuals
with hereditary retinoblastoma have a much higher risk of
radiotherapy-induced second malignancy compared with those
with sporadic disease.32,33 Thus far, no similar high-impact mu-
tation has been identiﬁed for HL, and sequencing of TP53, BRCA1,
BRCA2, and ATM in HL survivors with a second malignancy has
not substantiated a role for mutations in these genes as a cause of
subsequent cancer risk.16,34 Polygenic susceptibility provides an
alternative explanation for genetic susceptibility, whereby the el-
evated risk is enshrined in common genetic variants, which, in
Table 4. Risk of All Second Cancers and Site-Speciﬁc Cancers in Survivors of Hodgkin Lymphoma, by Family History
Cancer Site
Relatives With Cancer
P*
0 $ 1
No. SIR (95% CI) No. SIR (95% CI)
First-degree relative with cancer at any site
All second cancer 667 2.16 (2.00 to 2.33) 454 2.83 (2.58 to 3.10) , .001
First-degree relative with cancer at a concordant site
Colorectum 101 1.76 (1.45 to 2.14) 11 3.71 (2.05 to 6.70) .03
Lung 126 3.39 (2.85 to 4.03) 12 11.24 (6.38 to 19.79) , .001
Breast (female) 125 2.36 (1.98 to 2.81) 18 4.36 (2.60 to 6.55) .04
Squamous cell carcinoma (skin) 95 4.30 (3.52 to 5.26) 5 10.85 (4.52 to 26.08) .08
Non-Hodgkin lymphoma 121 7.83 (6.55 to 9.36) 4 14.43 (5.41 to 38.43) .27
Leukemia 77 6.37 (5.10 to 5.97) 2 14.31 (3.58 to 57.21) .32
Abbreviation: SIR, standardized incidence ratio.
*P values represent a test for trend
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Fig 1. Cumulative incidence of breast cancer in female survivors of Hodgkin
lymphoma, by age at Hodgkin lymphoma diagnosis, with death treated as
a competing risk. The solid blue line represents women diagnosed with Hodgkin
lymphoma at younger than 35 years of age, and the solid gold line represents
women diagnosed with Hodgkin lymphoma at 35 years of age or older. The
dashed blue line represents women in the population younger than 35 years of
age, and the dashed gold line represents women in the population 35 years of
age or older.
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isolation, exert small effects but act in concert to have a relatively
profound impact. Such an assertion is supported by the recent
ﬁndings that variation in FGFR2 and PRDM1 inﬂuences the risk of
second cancer in HL survivors.35,36 For lung cancer, we were able to
demonstrate a greater than additive interaction between family
history of lung cancer and HL treatment, which may be the
consequence of additional shared nongenetic risk factors, most
probably a propensity to smoke. This interaction is of signiﬁcant
importance because it may explain, in part, why no signiﬁcant
change in second lung cancer has been observed despite modiﬁ-
cations in treatment regimens. The number of cases of breast and
colorectal cancer did not permit the rejection of any interaction
model.
Survival of patients with HL after diagnosis of a second cancer
was not signiﬁcantly worse in those with an affected FDR.
Moreover, noninferiority of survival in individuals with a family
history of cancer has been described in colorectal, breast, and
prostate cancer.37-39 Although it remains to be established, reasons
for this may include increased cancer surveillance, resulting in
presentation at earlier stages of disease,40,41 improved health-
related behavior,42 or differences in tumor biology and response
to therapy.
Our study has major strengths. First, we have avoided as-
certainment bias in patient selection because our cohort analy-
sis was based on the Swedish population, for which there is near
complete case registration with long-term follow-up.20 Second, the
Swedish Family-Cancer Project Database includes a large number
of individuals linked to family members, and this has allowed us to
uniquely study the inﬂuence of family history on cancer risk.19 We
do acknowledge, however, that a limitation of our study is the
reliance on year of treatment as an effective surrogate for type of
treatment and that we did not have the opportunity to incorporate
information on risk factors such as smoking. However, most of the
familial risk of lung cancer is a result of a predisposition to smoke.
Hence, by performing an interactive analysis, we addressed this
area.
Despite these caveats, our ﬁndings further substantiate the
signiﬁcant cancer risks associated with survivorship from HL and
that these are modiﬁed by a family history of cancer. In addition,
our ﬁndings are of importance in a primary health care setting
where many surviving patients with HL are treated (for other
symptoms and diseases) after the ﬁrst 5 years of follow-up. Long-
term understanding of the biologic basis of these associations offers
the prospect of personalizing therapy in HL. However, such in-
formation has current value clinically, when planning risk-adapted
therapy for patients with HL. Furthermore, our ﬁndings with
respect to lung cancer emphasize the importance of instigating
programs to reduce smoking in patients with HL. Finally, as well as
offering breast cancer screening to women who have received
supradiaphragmatic radiotherapy,43,44 obtaining family history
information has a place in informing the long-term follow-up
screening of all patients with HL.
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